An African horse sickness virus serotype 4 recombinant canarypox virus vaccine elicits specific cell-mediated immune responses in horses

Veterinary Immunology and Immunopathology

Volumn 149, Issue 1-2, 2012, Pages 76-85

  El Garch, H ^a   Crafford, J E ^b   Amouyal, P ^a   Durand, P Y ^a   Edlund Toulemonde, C ^a   Lemaitre, L ^a   Cozette, V ^a   Guthrie, A ^b   Minke, J M ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

African horse sickness virus serotype 4 (AHSV4); Cell mediated immunity (CMI); Recombinant canarypox based vaccine (ALVAC )

Indexed keywords

ALVAC; ALVAC AHSV4 VACCINE; CAPSID PROTEIN; GAMMA INTERFERON; PROTEIN VP2; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

AFRICAN HORSE SICKNESS; AFRICAN HORSE SICKNESS VIRUS; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CANARYPOX VIRUS; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG RESPONSE; FEMALE; INFECTION PREVENTION; MALE; NONHUMAN; SEROTYPE; TREATMENT OUTCOME;

AFRICAN HORSE SICKNESS; AFRICAN HORSE SICKNESS VIRUS; ANIMALS; CANARYPOX VIRUS; CAPSID PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HORSES; IMMUNITY, CELLULAR; IMMUNIZATION; INTERFERON-GAMMA; MALE; VACCINES, SYNTHETIC; VIRAL VACCINES;

AFRICAN HORSESICKNESS VIRUS; CANARYPOX VIRUS; EQUIDAE; MIRIDAE;

EID: 84865541218     PISSN: 01652427     EISSN: 18732534     Source Type: Journal    
DOI: 10.1016/j.vetimm.2012.06.009     Document Type: Article

References (51)

1. Adams A.A., Sturgill T.L., Breathnach C.C., Chambers T.M., Siger L., Minke J.M., Horohov D.W. Humoral and cell-mediated immune responses of old horses following recombinant canarypox virus vaccination and subsequent challenge infection. Vet. Immunol. Immunopathol. 2011, 139:128-140.
2. Andrew M., Whiteley P., Janardhana V., Lobato Z., Gould A., Coupar B. Antigen specificity of the ovine cytotoxic T lymphocyte response to bluetongue virus. Vet. Immunol. Immunopathol. 1995, 47:311-322.
3. Baume D.M., Caligiuri M.A., Manley T.J., Daley J.F., Ritz J. Differential expression of CD8 alpha and CD8 beta associated with MHC-restricted and non-MHC-restricted cytolytic effector cells. Cell Immunol. 1990, 131:352-365.
4. Boone J.D., Balasuriya U.B., Karaca K., Audonnet J.C., Yao J., He L., Nordgren R., Monaco F., Savini G., Gardner I.A., Maclachlan N.J. Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep. Vaccine 2007, 25:672-678.
5. Burrage T.G., Trevejo R., Stone-Marschat M., Laegreid W.W. Neutralizing epitopes of African horsesickness virus serotype 4 are located on VP2. Virology 1993, 196:799-803.
6. Castillo-Olivares J., Calvo-Pinilla E., Casanova I., Bachanek-Bankowska K., Chiam R., Maan S., Nieto J.M., Ortego J., Mertens P.P. A modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR -/- mouse model. PLoS One 2011, 6(1):16503. 26.
7. Chiam R., Sharp E., Maan S., Rao S., Mertens P., Blacklaws B., Davis-Poynter N., Wood J., Castillo-Olivares J. Induction of antibody responses to African horse sickness virus (AHSV) in ponies after vaccination with recombinant modified vaccinia Ankara (MVA). PLoS One 2009, 4:e5997.
8. El Garch H., Minke J.M., Rehder J., Richard S., Edlund Toulemonde C., Dinic S., Andreoni C., Audonnet J.C., Nordgren R., Juillard V. A West Nile virus (WNV) recombinant canarypox virus vaccine elicits WNV-specific neutralizing antibodies and cell-mediated immune responses in the horse. Vet. Immunol. Immunopathol. 2008, 123:230-239.
9. Gould E.A., Higgs S. Impact of climate change and other factors on emerging arbovirus diseases. Trans. R. Soc. Trop. Med. Hyg. 2009, 103:109-121.
10. Guthrie A.J., Quan M., Lourens C.W., Audonnet J.C., Minke J.M., Yao J., He L., Nordgren R., Gardner I.A., Maclachlan N.J. Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus. Vaccine 2009, 27:4434-4438.
11. Horowitz A., Behrens R.H., Okell L., Fooks A.R., Riley E.M. NK cells as effectors of acquired immune responses: effector CD4+ T cell-dependent activation of NK cells following vaccination. J. Immunol. 2010, 185:2808-2818.
12. House J.A. Future international management of African horse sickness vaccines. Arch. Virol. Suppl. 1998, 14:297-304.
13. House J.A., Lombard M., Dubourget P., House C., Mebus C.A. Further studies on the efficacy of an inactivated African horse sickness serotype 4 vaccine. Vaccine 1994, 12:142-144.
14. Howell P.G., Groenewald D., Visage C.W., Bosman A.M., Coetzer J.A., Guthrie A.J. The classification of seven serotypes of equine encephalosis virus and the prevalence of homologous antibody in horses in South Africa. Onderstepoort J. Vet. Res. 2002, 69:79-93.
15. Janardhana V., Andrew M.E., Lobato Z.I., Coupar B.E. The ovine cytotoxic T lymphocyte responses to bluetongue virus. Res. Vet. Sci. 1999, 67:213-221.
16. Jeggo M.H., Gumm I.D., Taylor W.P. Clinical and serological response of sheep to serial challenge with different bluetongue virus types. Res. Vet. Sci. 1983, 34:205-211.
17. Jeggo M.H., Wardley R.C., Brownlie J. A study of the role of cell-mediated immunity in bluetongue virus infection in sheep, using cellular adoptive transfer techniques. Immunology 1984, 52:403-410.
18. Jeggo M.H., Wardley R.C., Brownlie J. Importance of ovine cytotoxic T cells in protection against bluetongue virus infection. Prog. Clin. Biol. Res. 1985, 178:477-487.
19. Jones L.D., Chuma T., Hails R., Williams T., Roy P. The non-structural proteins of bluetongue virus are a dominant source of cytotoxic T cell peptide determinants. J. Gen. Virol. 1996, 77(Pt 5):997-1003.
20. Jones L.D., Williams T., Bishop D., Roy P. Baculovirus-expressed nonstructural protein NS2 of bluetongue virus induces a cytotoxic T-cell response in mice which affords partial protection. Clin. Diagn. Lab. Immunol. 1997, 4:297-301.
21. Laviada M.D., Arias M., Sanchez-Vizcaino J.M. Characterization of African horsesickness virus serotype 4-induced polypeptides in Vero cells and their reactivity in Western immunoblotting. J. Gen. Virol. 1993, 74(Pt 1):81-87.
22. Lobato Z.I., Coupar B.E., Gray C.P., Lunt R., Andrew M.E. Antibody responses and protective immunity to recombinant vaccinia virus-expressed bluetongue virus antigens. Vet. Immunol. Immunopathol. 1997, 59:293-309.
23. Maclachlan N.J., Guthrie A.J. Re-emergence of bluetongue, African horse sickness, and other orbivirus diseases. Vet. Res. 2010, 41:35.
24. Martinez-Torrecuadrada J.L., Diaz-Laviada M., Roy P., Sanchez C., Vela C., Sanchez-Vizcaino J.M., Casal J.I. Full protection against African horsesickness (AHS) in horses induced by baculovirus-derived AHS virus serotype 4 VP2, VP5 and VP7. J. Gen. Virol. 1996, 77(Pt 6):1211-1221.
25. Martinez-Torrecuadrada J.L., Iwata H., Venteo A., Casal I., Roy P. Expression and characterization of the two outer capsid proteins of African horsesickness virus: the role of VP2 in virus neutralization. Virology 1994, 202:348-359.
26. Martinez-Torrecuadrada J.L., Langeveld J.P., Meloen R.H., Casal J.I. Definition of neutralizing sites on African horse sickness virus serotype 4 VP2 at the level of peptides. J. Gen. Virol. 2001, 82:2415-2424.
27. Martinez-Torrecuadrada J.L., Langeveld J.P., Venteo A., Sanz A., Dalsgaard K., Hamilton W.D., Meloen R.H., Casal J.I. Antigenic profile of African horse sickness virus serotype 4 VP5 and identification of a neutralizing epitope shared with bluetongue virus and epizootic hemorrhagic disease virus. Virology 1999, 257:449-459.
28. Minke J.M., El-Hage C.M., Tazawa P., Homer D., Lemaitre L., Cozette V., Gilkerson J.R., Kirkland P.D. Evaluation of the response to an accelerated immunisation schedule using a canarypox-vectored equine influenza vaccine, shortened interdose intervals and vaccination of young foals. Aust. Vet. J. 2011, 89(Suppl. 1):137-139.
29. Minke J.M., Siger L., Cupillard L., Powers B., Bakonyi T., Boyum S., Nowotny N., Bowen R. Protection provided by a recombinant ALVAC((R))-WNV vaccine expressing the prM/E genes of a lineage 1 strain of WNV against a virulent challenge with a lineage 2 strain. Vaccine 2011, 29:4608-4612.
30. Minke J.M., Fischer L., Baudu P., Guigal P.M., Sindle T., Mumford J.A., Audonnet J.C. Use of DNA and recombinant canarypox viral (ALVAC) vectors for equine herpes virus vaccination. Vet. Immunol. Immunopathol. 2006, 111:47-57.
31. Minke J.M., Siger L., Karaca K., Austgen L., Gordy P., Bowen R., Renshaw R.W., Loosmore S., Audonnet J.C., Nordgren B. Recombinant canarypoxvirus vaccine carrying the prM/E genes of West Nile virus protects horses against a West Nile virus-mosquito challenge. Arch. Virol. Suppl. 2004, 221-230.
32. Minke J.M., Toulemonde C.E., Coupier H., Guigal P.M., Dinic S., Sindle T., Jessett D., Black L., Bublot M., Pardo M.C., Audonnet J.C. Efficacy of a canarypox-vectored recombinant vaccine expressing the hemagglutinin gene of equine influenza H3N8 virus in the protection of ponies from viral challenge. Am. J. Vet. Res. 2007, 68:213-219.
33. Moebius U., Kober G., Griscelli A.L., Hercend T., Meuer S.C. Expression of different CD8 isoforms on distinct human lymphocyte subpopulations. Eur. J. Immunol. 1991, 21:1793-1800.
34. O'Neill T., Kydd J.H., Allen G.P., Wattrang E., Mumford J.A., Hannant D. Determination of equid herpesvirus 1-specific, CD8+, cytotoxic T lymphocyte precursor frequencies in ponies. Vet. Immunol. Immunopathol. 1999, 70:43-54.
35. Osburn B.I. Immune responses to orbiviruses. Second International Symposium on Bluetongue, African Horse Sickness and Related Orbiviruses 1992, 511-524. CRC Press, Boca Raton. T.E. Walton, B.I. Osburn (Eds.).
36. Paillot R., Daly J.M., Juillard V., Minke J.M., Hannant D., Kydd J.H. Equine interferon gamma synthesis in lymphocytes after in vivo infection and in vitro stimulation with EHV-1. Vaccine 2005, 23:4541-4551.
37. Paillot R., Ellis S.A., Daly J.M., Audonnet J.C., Minke J.M., Davis-Poynter N., Hannant D., Kydd J.H. Characterisation of CTL and IFN-gamma synthesis in ponies following vaccination with a NYVAC-based construct coding for EHV-1 immediate early gene, followed by challenge infection. Vaccine 2006, 24:1490-1500.
38. Paillot R., Kydd J.H., Sindle T., Hannant D., Edlund Toulemonde C., Audonnet J.C., Minke J.M., Daly J.M. Antibody and IFN-gamma responses induced by a recombinant canarypox vaccine and challenge infection with equine influenza virus. Vet. Immunol. Immunopathol. 2006, 112:225-233.
39. Paillot R., Kydd J.H., MacRae S., Minke J.M., Hannant D., Daly J.M. New assays to measure equine influenza virus-specific Type 1 immunity in horses. Vaccine 2007, 25:7385-7398.
40. Poulet H., Minke J., Pardo M.C., Juillard V., Nordgren B., Audonnet J.C. Development and registration of recombinant veterinary vaccines. The example of the canarypox vector platform. Vaccine 2007, 25:5606-5612.
41. Pretorius A., Van Kleef M., Van Wyngaardt W., Heath J. Virus-specific CD8(+) T-cells detected in PBMC from horses vaccinated against African horse sickness virus. Vet. Immunol. Immunopathol. 2012, 146:81-86.
42. Rojas J.M., Rodriguez-Calvo T., Pena L., Sevilla N. T cell responses to bluetongue virus are directed against multiple and identical CD4(+) and CD8(+) T cell epitopes from the VP7 core protein in mouse and sheep. Vaccine 2011, 29(40):6848-6857.
43. Romito M., Du Plessis D.H., Viljoen G.J. Immune responses in a horse inoculated with the VP2 gene of African horsesickness virus. Onderstepoort J. Vet. Res. 1999, 66:139-144.
44. Roy P., Bishop D.H., Howard S., Aitchison H., Erasmus B. Recombinant baculovirus-synthesized African horsesickness virus (AHSV) outer-capsid protein VP2 provides protection against virulent AHSV challenge. J. Gen. Virol. 1996, 77(Pt 9):2053-2057.
45. Scanlen M., Paweska J.T., Verschoor J.A., van Dijk A.A. The protective efficacy of a recombinant VP2-based African horsesickness subunit vaccine candidate is determined by adjuvant. Vaccine 2002, 20:1079-1088.
46. Siger L., Bowen R., Karaca K., Murray M., Jagannatha S., Echols B., Nordgren R., Minke J.M. Evaluation of the efficacy provided by a recombinant canarypox-vectored equine West Nile virus vaccine against an experimental West Nile virus intrathecal challenge in horses. Vet. Ther. 2006, 7:249-256.
47. Siger L., Bowen R.A., Karaca K., Murray M.J., Gordy P.W., Loosmore S.M., Audonnet J.C., Nordgren R.M., Minke J.M. Assessment of the efficacy of a single dose of a recombinant vaccine against West Nile virus in response to natural challenge with West Nile virus-infected mosquitoes in horses. Am. J. Vet. Res. 2004, 65:1459-1462.
48. Soboll G., Hussey S.B., Minke J.M., Landolt G.A., Hunter J.S., Jagannatha S., Lunn D.P. Onset and duration of immunity to equine influenza virus resulting from canarypox-vectored (ALVAC) vaccination. Vet. Immunol. Immunopathol. 2010, 135:100-107.
49. Stone-Marschat M.A., Moss S.R., Burrage T.G., Barber M.L., Roy P., Laegreid W.W. Immunization with VP2 is sufficient for protection against lethal challenge with African horsesickness virus Type 4. Virology 1996, 220:219-222.
50. Tschetter J.R., Davis W.C., Perryman L.E., McGuire T.C. CD8 dimer usage on alpha beta and gama delta T lymphocytes from equine lymphoid tissues. Immunobiology 1998, 198:424-438.
51. Wade-Evans A.M., Romero C.H., Mellor P., Takamatsu H., Anderson J., Thevasagayam J., Fleming M.J., Mertens P.P., Black D.N. Expression of the major core structural protein (VP7) of bluetongue virus, by a recombinant capripox virus, provides partial protection of sheep against a virulent heterotypic bluetongue virus challenge. Virology 1996, 220:227-231.